Concepedia

Clinical and biological characteristics of myeloma patients influence response to elotuzumab combination therapy

Sophia Danhof, Susanne Strifler, Dorothea Hose, K. Martin Kortüm, Max Bittrich, Jochen Hefner, Hermann Einsele, Stefan Knop, Martin Schreder

Journal of Cancer Research and Clinical Oncology · 2018 · 18 citations · 27 references

DOIFull text

Open access

Concepts

References

27

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

Brian G.M. Durie, Sydney E. Salmon · Cancer · 1975 · 3.1K citations

, , +15

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

Antonio Palumbo, Asher Chanan‐Khan, Katja Weisel et al. · New England Journal of Medicine · 2016 · 1.5K citations · Full text

, , +17

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

Meletios Α. Dimopoulos, Albert Oriol, Hareth Nahi et al. · New England Journal of Medicine · 2016 · 1.4K citations · Full text

, , +16

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

Sagar Lonial, Meletios Α. Dimopoulos, Antonio Palumbo et al. · New England Journal of Medicine · 2015 · 1.3K citations · Full text

, , +16

Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma

Philip L. McCarthy, Kouros Owzar, Craig C. Hofmeister et al. · New England Journal of Medicine · 2012 · 1.1K citations · Full text

, , +15